19 -4 (90) 2026 - Agababyan I.R., Ismoilova Y.A. - NEW TREATMENT OPTIONS FOR ISCHEMIC HEART DISEASE EMPHASIS ON NON-DRUG THERAPY

NEW TREATMENT OPTIONS FOR ISCHEMIC HEART DISEASE EMPHASIS ON NON-DRUG THERAPY

Karimov A.R. - Samarkand State Medical University

Djumayev K.Sh. - Samarkand State Medical University

Mamishova N.O. - Samarkand State Medical University

Resume

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver conditions worldwide and is closely associated with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes mellitus. In recent years, particular attention has been given to non-pharmacological methods for treating NAFLD, which are considered the foundation of therapy and prevention of disease progression. Current non-pharmacological treatment options for NAFLD include lifestyle modification, weight loss, therapeutic diet, increased physical activity, and correction of sleep and psycho-emotional state. A 7-10% reduction in body weight has been proven to decrease liver steatosis, inflammation, and fibrosis. Therefore, non-pharmacological therapy is a key approach in the management of NAFLD and should be implemented for all patients as a foundational treatment, especially in the early stages of the disease.

Key words: non-alcoholic fatty liver disease, steatosis, non-drug treatment, insulin, insulin resistance.

First page

132

Last page

139

For citation:Agababyan I.R., Ismoilova Y.A., Mamishova N.O. - NEW TREATMENT OPTIONS FOR ISCHEMIC HEART DISEASE EMPHASIS ON NON-DRUG THERAPY//New Day in Medicine 4(90)2026 132-139 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

1. Agababyan IR, Pulatova KS, Rofeev MS. Metabolic syndrome as one of the main factors of arterial hypertension development. Achievement of Science and Education. 2019;(10):51.
2. Agababyan I, Soliyeva S, Ismoilova Y. Condition of coronary arteries and change of lipid profile in coronary heart disease. Annals of the Romanian Society for Cell Biology. 2021:207–213.
3. Agababyan IR, Jabbarova N. Opportunities for using sodium-glucose cotransporter inhibitor type 2 in comprehensive treatment of non-alcoholic fatty liver disease: a literature review. Kardiologija v Belarusi. 2024;16(4):392–400.
4. Agababyan IR, Kobilova NA. Colchicine effect on C-reactive protein levels in patients with coronary heart disease after myocardial revascularization. Kardiologija v Belarusi. 2023;15(3):355–361.
5. Aghababyan I, Ismoilova Y. Strategy for the treatment of chronic heart failure in a specialized hospital. Kardiologija v Belarusi. 2023;15(5):618–627.
6. Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Molecular Metabolism. 2021;50:101143. doi:10.1016/j.molmet.2021.101143
7. Rubenovna AI, et al. Analysis of the effect of food stereotypes on disease in liver circuit disease. Asian Journal of Pharmaceutical and Biological Research. 2022;11(2).
8. Agababyan I, Yarasheva Z. Effect of percutaneous coronary intervention on central hemodynamic parameters in elderly patients. Kardiologija v Belarusi. 2024;16(3):337–341.
9. Agababyan I, Yarasheva Z, Nasretdinova M. The importance of echocardiography in the detection of early chronic heart failure in elderly patients. Kardiologija v Belarusi. 2022;14(3):313–318.
10. Younossi ZM, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Journal of Hepatology. 2024;80(5):694–701. doi:10.1016/j.jhep.2023.12.003

    file

    download